Validation in a broader cohort of patients was supported by an in silico analysis of the REMBRANDT glioma dataset, which showed a strong positive correlation between KDM2B expression with both CD133 and SOX2 (Fig. S2A). This evidence concerns the gene PROM1 and glioma.